Many Products Say “Clinically proven”. What makes DEX-C20 Different?
Many supplement products say that they’re “clinically tested” and “clinically proven”. You hear them all over the radio, on TV and in magazines. The reality is…many of these products have NEVER been clinically tested at all! Many supplement companies will identify an ingredient that was already clinically tested. They then use this ingredient in a formula and make product claims based on the one tested ingredient. Since there are usually many other ingredients in the product, testing on the complete formula is needed. Without testing on the complete formula, there is no way to know what effects are created by the specific combination of ingredients.
Very few supplement companies are doing independent testing of their complete formulas. Even most of the best-selling and best known supplements sold in major retail outlets are making “clinically proven” and “clinically tested” claims and yet often have not tested the complete product.
DEX-C20 is different because the key ingredient AND the complete formula have been clinically tested in independent studies by third party research centers. Delmar Labs, the maker of DEX-C20, is a division of a publicly traded pharmaceutical company. Being part of a pharmaceutical company, Delmar Labs has made a commitment to commissioning independent clinical trials on all of its supplement products. One of DEX-C20’s key ingredients is backed by two, independent double-blind clinical trials (a third is currently underway) and multiple safety studies, lab studies and university reviews. The complete DEX-C20 formula has been tested in one preliminary, independent efficacy study and is currently being tested in an independent 100 person double-blind study. The DEX-C20 study is being conducted by a leading third party, research facility that tests many prescription medications.
Completed Safety Studies:
All safety studies were done with OECD guidelines, accepted norms internationally.
- Acute Oral Toxicity study indicates that Slimaluma/patented Caralluma Fimbriata extract is safe up to the dosage of 5 gm per kg body weight which is 250% higher than any pharmaceutical safety dosage. It did not affect any vital organs like Liver, Kidney, heart or brain etc.
- Chronic Toxicity Study proves that Slimaluma/patented Caralluma Fimbriata extract is safe for long term usage. The dosage up to 1000 mg/ kg body weight did not affect any vital organs of any animals like Liver, Kidney, Heart etc.
- Mutagenicity study indicate that Slimaluma/patented Caralluma extract is non-Carcinogenic, or non-cancerous
- Chromosomal Abbreviation proves that Slimaluma/patented Caralluma extract is non-mutagenic in Human Peripheral Blood Lymphocytes
- Sub-Chronic study on Slimaluma/patented Caralluma extract is repeat of Chronic toxicity study
- CAMVA-BCOP (Chorioallantoic Membrane Vascular Assay and Bovine Corneal Opacity and Permeability) Test was conducted by independent lab in US suggests that Slimaluma/patented Caralluma extract does not cause ocular irritation.
- RIPT- Repeat Insult patch Testing illustrates that Slimaluma/patented Caralluma extract does not cause any skin irritation and allergic contact sterilization
- Test results for heavy metals and solvent residue by three independent labs in US illustrates that Slimaluma/patented Caralluma extract follows the most stringent law of California Prop-65.
Completed Human Studies:
- 50 person double blind placebo with Slimaluma/patented Caralluma extract- statistically significant reductions in appetite and waist circumference over placebo (published study)
- 25 person double-blind placebo with Slimaluma/patented Caralluma extract- statistically significant reduction in body weight over placebo
- 10 person efficacy study with DEX-C20 formula- 10 out of 10 patients lost weight. Weight loss ranged from 5-13 lbs. in 30 days. Average body fat reduction of 2.9%. Patients reported reduced appetite and increased energy without jitters.
In Process Human Studies:
4. 100 person, randomized, independent, multi-center, double-blind study with DEX-C20 formula (completion expected in July)
5. 100 person, randomized, double blind study with Slimaluma/patented Caralluma extract (completion expected in June)
